Thank you.
Mr. Stewart, I guess this question is for you.
In April, the U.S. FDA stopped AstraZeneca from using the Emergent BioSolutions plant in Baltimore, and halted production of the Janssen vaccine as it began an investigation into multiple areas of concern, including contamination and quality-control issues.
On April 25, Health Canada claimed to have verified that the 1.5 million doses of AstraZeneca vaccine imported into Canada from that facility met the quality specifications, but the FDA's inspection report noted that, “There is no assurance that other batches have not been subject to cross-contamination”.
How was Health Canada able to verify the quality of those doses when the FDA is unable to provide assurances that vaccine batches produced at the plant were not subject to cross-contamination?